Program
zastaprazan
Also written as “JP-1366 20mg tablet”, “JP-1366 10 mg” and “JP-1366”.
Its studies are mostly in Gastroesophageal Reflux · Ulcer · Peptic Ulcer · Esophagitis · Stomach Ulcer, led by Jeil Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jeil Pharmaceutical | 123 open or running | phase 3since Jun 28, 2022 | Dec 18, 2017 | Aug 2027phase 3 · NCT06439563 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 18, 2017First study: phase 1 study in Anti-Ulcer AgentsFirst studyNCT03383042 · 115 enrolled · Korea, Republic of
- Feb 21, 2020Phase 2 study in Gastroesophageal RefluxNCT04282954 · 188 enrolled · Korea, Republic of
- Nov 23, 20212 phase 1 studiesNCT05181124, NCT05194046
- Jun 28, 20222 phase 3 studiesNCT05448001, NCT05443984
- Jan 13, 2023Phase 1 study in HealthyNCT05712681 · 24 enrolled · Korea, Republic of
- Apr 3, 2023Phase 1 study in HealthyNCT05814809 · 30 enrolled · Korea, Republic of
- May 22, 2024Phase 3 study in Peptic UlcerNCT06439563 · 364 planned · Korea, Republic of
- Aug 29, 2025Phase 1 study in HealthyNCT07181538 · 55 enrolled · South Korea
- Nov 17, 2025Phase 1 study in Drug Drug Interaction (DDI)NCT07265466 · 96 planned · South Korea
- Jul 23, 2026Phase 3 study in Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)NCT07732075 · 384 planned
Ahead
- Aug 2027Primary completion: phase 3 study in Peptic UlcerNCT06439563
- Oct 30, 2028Primary completion: phase 3 study in Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD)NCT07732075
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07732075Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) | 3 | Not yet recruiting | Oct 30, 2028 | 384 |
| NCT07265466Drug Drug Interaction (DDI) · South Korea | 1 | Recruiting | Mar 30, 2026 | 96 |
| NCT07181538Healthy · South Korea | 1 | Completed | Feb 20, 2025 | 55 |
| NCT06439563Peptic Ulcer · Korea, Republic of | 3 | Recruiting | Aug 2027 | 364 |
| NCT05814809Healthy · Korea, Republic of | 1 | Completed | Oct 9, 2022 | 30 |
| NCT05712681Healthy · Korea, Republic of | 1 | Completed | May 4, 2023 | 24 |
| NCT05448001Stomach Ulcer · Korea, Republic of | 3 | Completed | Jul 10, 2024 | 329 |
| NCT05443984Erosive Esophagitis · Korea, Republic of | 3 | Completed | Jan 5, 2023 | 300 |
| NCT05194046Helicobacter Pylori Associated Gastrointestinal Disease · Korea, Republic of | 1 | Completed | Jan 16, 2021 | 29 |
| NCT05181124Anti-Ulcer Agents · Korea, Republic of | 1 | Completed | Mar 15, 2021 | 88 |
| NCT04282954Gastroesophageal Reflux · Korea, Republic of | 2 | Completed | Oct 20, 2020 | 188 |
| NCT03383042Anti-Ulcer Agents · Korea, Republic of | 1 | Completed | Nov 23, 2018 | 115 |
How it is read
Names in the registry
- “JP-1366 20mg tablet”, 3 entries
- “JP-1366 10 mg”, 2 entries
- “JP-1366”, 2 entries
- “JP-1366 20mg”, 2 entries
- “JP-1366 and clopidogrel”, 1 entry
Codes read as this program: JP1366.
Conditions, from the studies’ own filings
- Gastroesophageal Reflux, 2 studies
- Ulcer, 2 studies
- Peptic Ulcer, 1 study
- Esophagitis, 1 study
- Stomach Ulcer, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.